Here's Why You Should Retain DaVita Stock in Your Portfolio for Now

DaVita shares have gained 55.8% year to date, while the company cites IKC’s $40 million of second-quarter adjusted operating income above expectations and a roughly $3 sequential decline in patient care cost per treatment as potential growth and margin supports. Offsetting these factors, revenue per treatment fell about $2 sequentially, management expects full-year RPT growth of just 1–2%, and estimates commercial-mix pressure could cost roughly $70 million in 2027. 2026 consensus EPS remains unchanged at $14.57; third-quarter 2026 consensus revenue is $3.53 billion and EPS is $3.78.

Analysis

The key issue is earnings quality, not whether dialysis demand can grow. Volume leverage and IKC could diversify profit drivers, but neither is yet a clean offset to weaker commercial mix: IKC’s reported contribution is sensitive to revenue-recognition timing, while higher G&A can absorb incremental clinic utilization. That makes current earnings less durable than headline growth suggests. After a large year-to-date rerating, stable estimates leave less room for upside surprise; a beat driven by timing or cost relief may not sustain the multiple without evidence of recurring IKC economics and U.S. dialysis operating-income growth.

Over the next 1–3 months, focus on the next report’s treatment volumes, revenue per treatment, U.S. dialysis operating income, and G&A growth—not just EPS. Over 6–18 months, commercial-payer mix is the structural swing factor; Medicare Advantage contract additions could help IKC, but contract counts alone do not establish profitable economics. Fresenius Medical Care may face similar U.S. payer-mix pressures, though the article provides no comparative data to support a pair trade. The contrarian risk is that investors treat sequential cost improvement as durable margin expansion when some benefit may be mix- or timing-driven. Conversely, if volume growth and cost control persist while IKC converts into recurring earnings, skepticism about the growth mix could prove too high.

Key Decisions for Investors

• Do not chase DVA after its sharp rerating; for existing positions, consider trimming into strength rather than initiating a directional short without valuation and positioning data.
• Reassess after the next earnings release: require improvement in U.S. dialysis operating income alongside volume gains, with G&A growth moderating and revenue per treatment tracking management’s outlook, before adding exposure.
• Treat IKC as an upside watch item, not yet a valuation anchor. Verify recurring operating contribution, revenue-recognition timing, and economics of new Medicare Advantage contracts.
• Thesis improves if operating income converts volume growth into sustained margin progress; it weakens if commercial mix depresses revenue per treatment more than expected or overhead continues to absorb leverage.